Eleva is a privately-held company based in Freiburg, Germany that has created a moss-based production platform to develop drug candidates into clinical phases. This platform produces biologics like antibodies, replacement enzymes, and fusion toxins, which are complex posttranslational modifications like glycosylations to produce supreme biologics. Eleva's mission is to enable healthcare organizations to get recombinant proteins for the treatment of patients.